Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

The US Senate today confirmed Robert F Kennedy Jr as Health and Human Services Secretary, after a vote that largely followed ...

The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Data-driven insights powered by advanced analytics and artificial intelligence (AI) help optimise project schedules, allocate ...

The company has assembled a team that hails from DeepMind and Microsoft, AI in drug discovery specialist Exscientia, genomics and machine learning company Zymergen (bought by Ginkgo Bioworks in 2022), ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...